Literature DB >> 16934708

Group A streptococcus.

Judith M Martin1, Michael Green.   

Abstract

Group A streptococci (GAS) are gram positive cocci that can be divided into more than 100 M-serotypes or emm types based on their M proteins. Their virulence is related directly to the M protein on the cell surface that inhibits phagocytosis. Although it is more commonly thought of in the context of causing clinical illness, Streptococcus pyogenes can colonize the pharynx and skin. Infections due to GAS include pharyngitis, impetigo, ecthyma, erysipelas, and cellulitis. These infections, as well as the manifestations of invasive disease including streptococcal toxic shock syndrome and necrotizing fasciitis, will be reviewed in this article. Also included will be the nonsuppurative complications of GAS infections, acute rheumatic fever and post streptococcal glomerular nephritis. GAS is an important cause of infections in children in both the ambulatory and hospital settings. Current efforts aimed at the development of a vaccine are warranted but remain in preliminary stages at this time.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16934708     DOI: 10.1053/j.spid.2006.07.001

Source DB:  PubMed          Journal:  Semin Pediatr Infect Dis        ISSN: 1045-1870


  21 in total

1.  Regulation of virulence gene expression in Streptococcus pyogenes: determinants of differential mRNA decay.

Authors:  Julia V Bugrysheva; June R Scott
Journal:  RNA Biol       Date:  2010-09-01       Impact factor: 4.652

2.  Current practice about the evaluation of antibody to streptolysin O (ASO) levels by physicians working in Antananarivo, Madagascar.

Authors:  Norosoa Julie Zafindraibe; Zely Arivelo Randriamanantany; Davidra Hendriso Rajaonatahina; Ramamonjisoa Andriamahenina; Andry Rasamindrakotroka
Journal:  Afr Health Sci       Date:  2014-06       Impact factor: 0.927

Review 3.  The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza.

Authors:  Amber M Smith; Victor C Huber
Journal:  Viral Immunol       Date:  2017-11-17       Impact factor: 2.257

4.  Molecular and biological characterization of Streptococcal SpyA-mediated ADP-ribosylation of intermediate filament protein vimentin.

Authors:  Laura M Icenogle; Shawna M Hengel; Lisette H Coye; Amber Streifel; Carleen M Collins; David R Goodlett; Steve L Moseley
Journal:  J Biol Chem       Date:  2012-05-01       Impact factor: 5.157

5.  Streptococcus pyogenes CovRS mediates growth in iron starvation and in the presence of the human cationic antimicrobial peptide LL-37.

Authors:  Barbara J Froehlich; Christopher Bates; June R Scott
Journal:  J Bacteriol       Date:  2008-11-07       Impact factor: 3.490

6.  emm Types, virulence factors, and antibiotic resistance of invasive Streptococcus pyogenes isolates from Italy: What has changed in 11 years?

Authors:  Roberta Creti; Monica Imperi; Lucilla Baldassarri; Marco Pataracchia; Simona Recchia; Giovanna Alfarone; Graziella Orefici
Journal:  J Clin Microbiol       Date:  2007-05-09       Impact factor: 5.948

7.  Acute post-streptococcal glomerulonephritis in children of French Polynesia: a 3-year retrospective study.

Authors:  Odile Becquet; Jérôme Pasche; Hélène Gatti; Claude Chenel; Michel Abély; Patrice Morville; Christine Pietrement
Journal:  Pediatr Nephrol       Date:  2009-10-30       Impact factor: 3.714

8.  Sequence type and emm type diversity in Streptococcus pyogenes isolates causing invasive disease in Norway between 1988 and 2003.

Authors:  Roger Meisal; E Arne Høiby; Ingeborg S Aaberge; Dominique A Caugant
Journal:  J Clin Microbiol       Date:  2008-04-16       Impact factor: 5.948

9.  Vigilant keratinocytes trigger pathogen-associated molecular pattern signaling in response to streptococcal M1 protein.

Authors:  Sandra T Persson; Laura Wilk; Matthias Mörgelin; Heiko Herwald
Journal:  Infect Immun       Date:  2015-09-28       Impact factor: 3.441

10.  Community management of endemic scabies in remote aboriginal communities of northern Australia: low treatment uptake and high ongoing acquisition.

Authors:  Sophie La Vincente; Therese Kearns; Christine Connors; Scott Cameron; Jonathan Carapetis; Ross Andrews
Journal:  PLoS Negl Trop Dis       Date:  2009-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.